All In Biotech

Drug Trial Radar · NCT02633501

P03277 Dose Finding Study in Central Nervous System (CNS) Magnetic Resonance Imaging (MRI)

Last checked: Nov 20, 2026Latest source record: Oct 25, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 312 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

312

Actual

Start

Jun 2016

Primary completion

Jan 2018

Study completion Jan 2018

Sponsor

Lead sponsor
GuerbetIndustry
Sponsor type
Industry
First posted
Dec 17, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Diagnostic
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study was to determine a safe and effective dose of a new gadolinium-based contrast agent (GBCA) P03277 based on the Contrast to Noise Ratio (CNR) when comparing with gadobenate dimeglumine (MultiHance®) at 0.1 mmol/kg body weight (BW). Contrast to Noise Ratio (CNR), a well-known quantitative parameter directly related to contrast medium/GBCA efficacy, was chosen as the primary endpoint in order to have a precise determination of P03277 clinical dose. This was a multi-center, international, prospective, double-blind, randomized, controlled, parallel dose groups, cross-over with comparator study in male and female subjects presenting with known or highly suspected focal areas of disruption of the Blood Brain Barrier including at least one expected enhancing lesion of minimum 5 mm, who were scheduled to undergo a routine contrast-enhanced Magnetic Resonance Imaging (MRI) of Central Nervous System.

Conditions

  • CNS Lesion
  • Blood Brain Barrier Defect

Interventions

  • P03277Drug

    Single intravenous (IV) bolus injection at a rate of 2 mL/second

  • Gadobenate dimeglumineDrug

    Single IV bolus injection at a rate of 2 mL/second

  • MRIDevice

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Contrast to Noise Ratio (CNR) DifferenceTime frame: 1 day procedure

Locations

28 sites in 8 countries. Site status is shown where the registry gives one.

  • Northwestern memorial hospital

    Chicago, Illinois

  • Beth israel deaconess medical center

    Boston, Massachusetts

  • QUEST Research Institute

    Farmington Hills, Michigan

  • Penn State milton S. Hershey Medical center

    Hershey, Pennsylvania

  • University of Pensylvania medical center

    Philadelphia, Pennsylvania

  • Temple university hospital

    Philadelphia, Pennsylvania

  • Rhode Island hospital

    Providence, Rhode Island

  • Medical University of South Carolina

    Charleston, South Carolina

  • University of texas McGovern medical school

    Houston, Texas

  • University of Washington

    Seattle, Washington

  • ZNA campus Middelheim

    Antwerp, Belgium

  • Universitair Ziekenhuis Brussel

    Brussels, Belgium

  • Fakultni nemocnice Olomouc

    Olomouc, Czechia

  • Neurology Clinic-Semmelweis Medical University

    Budapest, Hungary

  • Pecsi Tudomany Egyetem Klinikai kozpont Idegsebeszeti Klinica

    Pécs, Hungary

  • Ospedali Riuniti di Ancona

    Ancona, Italy

  • Ospedale san Raffaele

    Milan, Italy

  • AO S. Andrea Universita La Sapienza

    Roma, Italy

  • Azienda policlinico Umberto

    Roma, Italy

  • Centro medico ABC santa fe

    Mexico City, Mexico

  • Axis heilsa

    Monterrey, Mexico

  • Clinical research institute SC

    Tlalnepantla, Mexico

  • Centrum Onkologii Instytut im. Marii Sklodowskiej-Curie, Oddzial w Gliwicach

    Gliwice, Poland

  • krakowski Szpital specjalistyczny il Jana Pawla II

    Krakow, Poland

  • Samodzielny publiczny szpital

    Lublin, Poland

  • Asan medical center

    Seoul, South Korea

  • Samsung medical center

    Seoul, South Korea

  • Seoul National university hospital

    Seoul, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.